(Total Views: 668)
Posted On: 09/27/2021 11:17:16 AM
Post# of 22465
"We learned Neurolytixs acknowledges QTMM as a partner and they do in fact hold patents for brain disease/injuries biomarkers.
If nothing else it adds credibility to QTMM lastest update."
As Squires stated in the last updated, Neurolytixs has pending patents. The bottom 3 are clearly provisional since they start with 62- and have not been published.
The first patent is an application https://patents.google.com/patent/WO201614980...6%2f149808 which has been published but is still pending. Looking deeper at https://portal.uspto.gov/pair/PublicPair , the US Application 15/560,056 was given a non-final rejection in June 2021 and an amendment was submitted in September.
Also note that the application has been assigned to LONDON HEALTH SCIENCES CENTRE RESEARCH INC by the inventors. It looks like Neurolytics is licensing the tech from London Health.
If nothing else it adds credibility to QTMM lastest update."
As Squires stated in the last updated, Neurolytixs has pending patents. The bottom 3 are clearly provisional since they start with 62- and have not been published.
The first patent is an application https://patents.google.com/patent/WO201614980...6%2f149808 which has been published but is still pending. Looking deeper at https://portal.uspto.gov/pair/PublicPair , the US Application 15/560,056 was given a non-final rejection in June 2021 and an amendment was submitted in September.
Also note that the application has been assigned to LONDON HEALTH SCIENCES CENTRE RESEARCH INC by the inventors. It looks like Neurolytics is licensing the tech from London Health.
Quote:
Neurolytixs Intellectual Property (Patents)
METABOLOMICS PROFILING OF CENTRAL NERVOUS SYSTEM INJURY (2016), WO 2016/149808
DETERMINING CENTRAL NERVOUS SYSTEM INJURY AND RECOVERY (2020), 62/988169
DIAGNOSIS AND THERAPY OF TRAUMATIC BRAIN INJURY (2020), 63/104680
DETERMINING MILD TRAUMATIC BRAIN INJURY, RECOVERY AND TREATMENT (2021), 63/211771
(0)
(0)
